Shares of Zafgen Inc. (NASDAQ:ZFGN) rose 2.6% during mid-day trading on Friday . The stock traded as high as $6.72 and last traded at $6.64, with a volume of 103,536 shares traded. The stock had previously closed at $6.47.

ZFGN has been the subject of several analyst reports. Royal Bank Of Canada reissued an “outperform” rating and issued a $19.00 price objective on shares of Zafgen in a research note on Tuesday, April 5th. Leerink Swann reaffirmed a “hold” rating and set a $6.00 target price on shares of Zafgen in a research report on Monday, April 11th. FBR & Co reaffirmed a “buy” rating and set a $20.00 target price on shares of Zafgen in a research report on Monday, April 4th. Finally, Zacks Investment Research raised shares of Zafgen from a “hold” rating to a “buy” rating and set a $7.25 target price on the stock in a research report on Thursday, May 12th. Four research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $11.94.

The firm’s market cap is $182.72 million. The stock’s 50-day moving average is $6.43 and its 200 day moving average is $6.58.

Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.09. During the same quarter in the previous year, the firm posted ($0.53) EPS. On average, equities research analysts predict that Zafgen Inc. will post ($2.81) EPS for the current year.

A hedge fund recently bought a new stake in Zafgen stock. Oxford Asset Management bought a new stake in shares of Zafgen Inc. (NASDAQ:ZFGN) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 236,362 shares of the biopharmaceutical company’s stock, valued at approximately $1,497,000. Oxford Asset Management owned 0.87% of Zafgen at the end of the most recent quarter.

Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.